Evidence map›Paper›PMID 33381110›Full record

ArticleFrontiers in immunology2020

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer.

Sarah Musa Hammoudeh, Thenmozhi Venkatachalam, Abdul Wahid Ansari, Riyad Bendardaf, Qutayba Hamid, Mohamed Rahmani, Rifat Hamoudi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Sarah Musa HammoudehClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Thenmozhi VenkatachalamSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Abdul Wahid AnsariSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Riyad BendardafClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Qutayba HamidClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Mohamed RahmaniClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Rifat HamoudiClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
University of Sharjah · AEChristie (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunomodulation and chronic inflammation are important mechanisms utilized by cancer cells to evade the immune defense and promote tumor progression. Therefore, various efforts were focused on the development of approaches to reprogram the immune response to increase the immune detection of cancer cells and enhance patient response to various types of therapy. A number of regulatory proteins were investigated and proposed as potential targets for immunomodulatory therapeutic approaches including p53 and Snail. In this study, we investigated the immunomodulatory effect of disrupting Snail-p53 binding induced by the oncogenic KRAS to suppress p53 signaling. We analyzed the transcriptomic profile mediated by Snail-p53 binding inhibitor GN25 in non-small cell lung cancer cells (A549) using Next generation whole RNA-sequencing. Notably, we observed a significant enrichment in transcripts involved in immune response pathways especially those contributing to neutrophil (IL8) and T-cell mediated immunity (BCL6, and CD81). Moreover, transcripts associated with NF-κB signaling were also enriched which may play an important role in the immunomodulatory effect of Snail-p53 binding. Further analysis revealed that the immune expression signature of GN25 overlaps with the signature of other therapeutic compounds known to exhibit immunomodulatory effects validating the immunomodulatory potential of targeting Snail-p53 binding. The effects of GN25 on the immune response pathways suggest that targeting Snail-p53 binding might be a potentially effective therapeutic strategy.

Indexed as

MutationApoptosisCarcinoma, Non-Small-Cell LungCell CycleCell Line, TumorComputational BiologyGene Expression ProfilingHumansImmunity, CellularImmunomodulationLung NeoplasmsNeutrophilsNF-kappa BProto-Oncogene Proteins p21(ras)Signal TransductionSnail Family Transcription FactorsKRAS protein, humanNF-kappa BProto-Oncogene Proteins p21(ras)Snail Family Transcription FactorsTumor Suppressor Protein p53immunomodulationneutrophil-mediated anticancer immunitynon-small cell lung cancersnail-p53 bindingsystems immunologyT-cell mediated anticancer immunitytumor sensitization

Identifiers

PMID33381110
PMCPMC7768232
OpenAlexW3113042952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.